{"id":"W2089560299","doi":"10.3810/pgm.2010.01.2108","title":"Reaching HbA<sub>1c</sub>Goals with Saxagliptin in Combination with Other Oral Antidiabetic Drugs","year":2010,"lang":"en","type":"review","venue":"Postgraduate Medicine","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"AstraZeneca","keywords":"Saxagliptin; Medicine; Glycemic; Type 2 diabetes; Vildagliptin; Hypoglycemia; Postprandial; Tolerability; Diabetes mellitus; Glycated hemoglobin; Dipeptidyl peptidase-4 inhibitor; Internal medicine; Metformin; Pharmacology; Endocrinology; Adverse effect; Sitagliptin","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001351518,0.0004275583,0.001223058,0.0007035228,0.000206156,0.0009300046,0.0003234029,0.0004407787,0.002652472],"category_scores_gemma":[0.001211753,0.0001243139,0.001076257,0.0005886537,0.0001572975,0.0005291006,0.0005916954,0.0016073,0.001111007],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000571764,"about_ca_system_score_gemma":0.0005891493,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007973052,"about_ca_topic_score_gemma":0.002295888,"domain_scores_codex":[0.9991186,0.0002555366,0.0001295317,0.00007151458,0.0003243714,0.0001003775],"domain_scores_gemma":[0.9996036,0.00008505509,0.00009640156,0.00003006215,0.00009072721,0.00009429711],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008367063,0.001703755,0.009424376,0.002353927,0.001109385,0.00106545,0.0001918921,0.001738101,0.0245153,0.001688297,0.04434506,0.9034973],"study_design_scores_gemma":[0.01508401,0.02311299,0.1702282,0.009485626,0.008179616,0.007986048,0.0007557413,0.02470667,0.06672812,0.01226351,0.6611617,0.0003077255],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.4027436,0.4551904,0.02019815,0.02394647,0.004930202,0.0008183099,0.001194001,0.001367026,0.08961189],"genre_scores_gemma":[0.7798738,0.1689843,0.01968395,0.01515029,0.004561031,0.0004734727,0.001919607,0.000157152,0.009196268],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002652472,"threshold_uncertainty_score":0.008873403,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03119454403990676,"score_gpt":0.3018268130513877,"score_spread":0.270632269011481,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}